<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333745</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300004693</org_study_id>
    <nct_id>NCT04333745</nct_id>
  </id_info>
  <brief_title>Influence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers</brief_title>
  <official_title>Influence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goals of this study are to determine the contribution of dietary oxalate&#xD;
      absorption, renal oxalate handling, and endogenous oxalate synthesis to urinary oxalate&#xD;
      excretion in normal Body Mass Index (BMI) and obese calcium oxalate kidney stone formers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Oxalate Excretion</measure>
    <time_frame>Baseline through Day 5</time_frame>
    <description>Urinary oxalate excretion from urine samples will be measured as mg/day</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Kidney Stone</condition>
  <arm_group>
    <arm_group_label>Controlled Dietary Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will consume the controlled diet for five days. After one day on the diet, subjects will provide three 24-hour urine collections. On the last dayof the diet, subjects will come in a fasted state to ingest a small amount of carbon-13 oxalate and sucralose, with hourly urine collections and blood samples being taken before and after the ingestion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Controlled Diet</intervention_name>
    <description>Participant will consume a controlled low oxalate diet for five days</description>
    <arm_group_label>Controlled Dietary Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carbon-13 Oxalate and Sucralose Ingestion</intervention_name>
    <description>Subjects will ingest a small amount of carbon-13 oxalate and sucralose, dissolved in water.</description>
    <arm_group_label>Controlled Dietary Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal Body Mass Index (≥ 18.5 to &lt; 25); Obese Body Mass Index (≥ 30 to ≤ 45)&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Willingness to consume controlled diet&#xD;
&#xD;
          -  Composition of most recent stone &gt; 50% calcium oxalate, no uric acid component&#xD;
&#xD;
          -  First time or recurrent calcium oxalate stone former&#xD;
&#xD;
          -  24-hour urine collections with creatinine values within 20% of appropriate ratio of&#xD;
             creatinine (mg)/body weight (kg) for gender, and with creatinine values that are&#xD;
             consistent between collections (within 20% of each other)&#xD;
&#xD;
          -  Willingness to stop supplements [vitamins, Ca (citrate or carbonate) and other&#xD;
             minerals, herbal supplements, nutritional aids, probiotics] for 14 days before start&#xD;
             and during study&#xD;
&#xD;
          -  Willingness to not undertake vigorous exercise during the controlled dietary study&#xD;
&#xD;
          -  Normal fasting blood Comprehensive Metabolic Panel&#xD;
&#xD;
          -  Hemoglobin A1c &lt; 6.5%&#xD;
&#xD;
          -  No food allergies or intolerance to any of the food in study menus&#xD;
&#xD;
          -  Permitted/willing to discontinue medications for kidney stone prevention, including&#xD;
             thiazides, allopurinol, and febuxostat and citrate preparations, for 14 days before&#xD;
             start and during the studies. They will be instructed to restart these medications at&#xD;
             the conclusion of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Abnormal fasting comprehensive metabolic panel (CMP)&#xD;
&#xD;
          -  Hemoglobin A1c (HbA1c) result ≥ 6.5%&#xD;
&#xD;
          -  Gout&#xD;
&#xD;
          -  Estimated Glomerular Filtration Rate (eGFR) &lt;60 ml/min/1.73m^2&#xD;
&#xD;
          -  Primary hyperoxaluria&#xD;
&#xD;
          -  Cystic fibrosis&#xD;
&#xD;
          -  Cystinuria&#xD;
&#xD;
          -  Uric acid stone former&#xD;
&#xD;
          -  Utilization of immunosuppressive medication&#xD;
&#xD;
          -  Nephrotic syndrome&#xD;
&#xD;
          -  Enteric hyperoxaluria&#xD;
&#xD;
          -  Gastrointestinal disorder that could impact oxalate transport&#xD;
&#xD;
          -  Sarcoidosis&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Renal tubular acidosis&#xD;
&#xD;
          -  Primary hyperparathyroidism&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Neurogenic bladder&#xD;
&#xD;
          -  Urinary diversion&#xD;
&#xD;
          -  Chronic diarrhea&#xD;
&#xD;
          -  Bariatric surgery&#xD;
&#xD;
          -  Active malignancy or treatment for malignancy within 12 months prior to screening&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast feeding/nursing&#xD;
&#xD;
          -  Females of child bearing age who are not able to use an effective method of birth&#xD;
             control during the study&#xD;
&#xD;
          -  Mental/medical condition that is likely to impede successful study completion&#xD;
&#xD;
          -  Illness including flu / common cold / fever 14 days before study and during study&#xD;
&#xD;
          -  Diarrhea or other abnormal gastrointestinal event (e.g. abnormal bowel movements) 14&#xD;
             days before study or during study&#xD;
&#xD;
          -  Antibiotic use within last 6 months (based on recommendations of the NIH Human&#xD;
             Microbiome Project, Protocol A)&#xD;
&#xD;
          -  Inability or unwillingness to undergo MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean Assimos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Demond Wiley</last_name>
    <phone>205-934-3671</phone>
    <email>kidneystone@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243-3353</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Demond Wiley</last_name>
      <phone>205-934-3671</phone>
      <email>kidneystone@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Dean Assimos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudeepa Bhattacharya</last_name>
      <email>Sudeepa.Bhattacharya@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Naim Maalouf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Dean Assimos, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>oxalate</keyword>
  <keyword>kidney stone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

